Fixed dose Salmeterol/fluticasone combo delivered through Synchrobreathe improves lung function and asthma control

The 12-week salmeterol/fluticasone fixed-dose combination (FDC) treatment was well tolerated and delivered by Synchrobreathe®, it further improved asthma control and lung function over time, says an article published in Therapeutic Advances in Respiratory Disease of SAGE Journals.

Traditionally, the majority of asthma care has been inhalation therapy with corticosteroids and long-acting 2-agonists. But in order to successfully transport the medication to the lungs and achieve adequate asthma control, the right inhaler technique must be used. As a result, Santhalingam Balamurugan and colleagues performed this research to assess asthma control and device usability in Indian patients with chronic asthma using salmeterol /fluticasone fixed-dose combination delivered using Synchrobreathe®, a breath-actuated inhaler (BAI) (EVOLVE study).

This study was an observational, multi-center, prospective, open-label, non-comparative investigation. It included 490 individuals with confirmed diagnoses of asthma who were either untreated or had their asthma out of control as a result of improper inhaler technique related to a previous device. The Asthma Control Questionnaire-6 (ACQ-6) score at week 12 was the main outcome, which measured a change from baseline.

The key findings of this study were:

1.In the intention-to-treat (ITT) group, the mean ACQ-6 score decreased from 2.2 ± 1.07 (baseline) to 0.4 ± 0.49 at week 12, and a minimal clinically significant difference of 0.5 was seen from week 4 onward.

2.In the ITT sample, the peak expiratory flow rate increased by 82.5 ± 75.74 ml/min (p 0.0001) at week 12.

3.The percentage of respondents who responded under control rose from 39.9% (week 4) to 77.1%. (week 12).

4.The majority of patients (91%) chose Synchrobreathe® and gave it extremely good ratings for usage, portability, patient confidence, and satisfaction.

5.Salmeterol /fluticasone FDC was well tolerated when given using Synchrobreathe®.

In conclusion, salmeterol/fluticasone (SFC) administered via Synchrobreathe® has a favorable safety profile and effectiveness, and it may have important therapeutic ramifications for enhancing asthma management in actual clinical situations. SFC Synchrobreathe® is an improved inhaler solution for asthmatics, even those who now use inadequate technique.

Reference:

Balamurugan, S., Sonia, D., Vikrant, D., Monotosh, K., Raj Shyam, S., Shamim, A., Vinay, K., Velayuthaswamy, N., Masood, A., Manohar Lal, G., Sonali, J., Abhijit, V., & Jaideep, G. (2022). Effectiveness and safety of salmeterol/fluticasone fixed-dose combination delivered through Synchrobreathe® in patients with asthma: the real-world EVOLVE study. In Therapeutic Advances in Respiratory Disease (Vol. 16, p. 175346662211372). SAGE Publications. https://doi.org/10.1177/17534666221137272